Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T20:41:21.529Z.
Calculation as of: 2026-10-06T20:41:21.529Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: b1e589d4888711efc6e495fe73fbc3b606428562d81b06b8c422d1cee3adbcc2
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Establishment Labs Holdings Inc.
Market Cap
$1.92B
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.94B
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.89B
Price/OCF Ratio
N/A
TTM Avg
35.45
3Y Avg
35.45
5Y Avg
35.45
Market Cap
$1.89B
Price/OCF Ratio
111.77
TTM Avg
74.69
3Y Avg
89.69
5Y Avg
89.69
Market Cap
$1.97B
Price/OCF Ratio
12.55
TTM Avg
15.11
3Y Avg
87.88
5Y Avg
147.64
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Establishment Labs Holdings Inc. (ESTA) | $1.92B | N/A | N/A | N/A | N/A |
| Mineralys Therapeutics, Inc. (MLYS)vs › | $1.94B | N/A | N/A | N/A | N/A |
| Agios Pharmaceuticals, Inc. (AGIO)vs › | $1.89B | N/A | 35.45 | 35.45 | 35.45 |
| AxoGen, Inc. (AXGN)vs › | $1.95B | 209.45 | 496.06 | 363.21 | 363.21 |
| Zymeworks Inc. (ZYME)vs › | $1.89B | N/A | 4.08 | 4.08 | 116.61 |
| Vir Biotechnology, Inc. (VIR)vs › | $1.96B | N/A | 2.40 | 3.08 | 3.08 |
| BioLife Solutions, Inc. (BLFS)vs › | $1.89B | 111.77 | 74.69 | 89.69 | 89.69 |
| Inspire Medical Systems, Inc. (INSP)vs › | $1.97B | 12.55 | 15.11 | 87.88 | 147.64 |
| Trevi Therapeutics, Inc. (TRVI)vs › | $1.87B | N/A | N/A | N/A | N/A |
| Fortrea Holdings Inc. (FTRE)vs › | $1.98B | 10.83 | 296.01 | 104.86 | 96.00 |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
